TW200733965A - Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea - Google Patents

Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea

Info

Publication number
TW200733965A
TW200733965A TW095145947A TW95145947A TW200733965A TW 200733965 A TW200733965 A TW 200733965A TW 095145947 A TW095145947 A TW 095145947A TW 95145947 A TW95145947 A TW 95145947A TW 200733965 A TW200733965 A TW 200733965A
Authority
TW
Taiwan
Prior art keywords
phenyl
pyrrolo
prodrugs
dichloro
pyrimidine
Prior art date
Application number
TW095145947A
Other languages
English (en)
Chinese (zh)
Inventor
Tracy Lee Boyden
Feng Guo
Susan Deborah Lagreca
Douglas Alan Lorenz
Ravi Mysore Shanker
Franzanne Vreeland
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of TW200733965A publication Critical patent/TW200733965A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW095145947A 2005-12-09 2006-12-08 Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea TW200733965A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74907005P 2005-12-09 2005-12-09

Publications (1)

Publication Number Publication Date
TW200733965A true TW200733965A (en) 2007-09-16

Family

ID=38123252

Family Applications (1)

Application Number Title Priority Date Filing Date
TW095145947A TW200733965A (en) 2005-12-09 2006-12-08 Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea

Country Status (8)

Country Link
AR (1) AR058293A1 (es)
DO (1) DOP2006000271A (es)
GT (1) GT200600496A (es)
NL (1) NL2000337A1 (es)
PE (1) PE20071037A1 (es)
TW (1) TW200733965A (es)
UY (1) UY29991A1 (es)
WO (1) WO2007066189A2 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143423A1 (en) * 2007-10-19 2009-06-04 Abbott Gmbh & Co. Kg Solid dispersion product containing n-aryl urea-based compound
BRPI0818340A2 (pt) * 2007-10-19 2015-04-22 Abbott Gmbh & Co Kg Produto de dispersão sólida de fármacos baseados em n-aril uréia
DK2358720T3 (en) * 2008-10-16 2016-06-06 Univ California Heteroarylkinaseinhibitorer fused-ring
CN102892768A (zh) 2009-12-30 2013-01-23 艾科尔公司 被取代的吡咯并氨基嘧啶化合物
EP2585048B1 (en) * 2010-06-23 2018-04-11 CymaBay Therapeutics, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
WO2012088266A2 (en) 2010-12-22 2012-06-28 Incyte Corporation Substituted imidazopyridazines and benzimidazoles as inhibitors of fgfr3
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US20140004192A1 (en) * 2012-04-13 2014-01-02 Ziopharm Oncology, Inc. Pharmaceutical formulations of indibulin and uses thereof
CA2876689C (en) 2012-06-13 2022-04-26 Incyte Corporation Substituted tricyclic compounds as fgfr inhibitors
US9388185B2 (en) 2012-08-10 2016-07-12 Incyte Holdings Corporation Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
MX2015003874A (es) 2012-09-26 2015-12-16 Univ California Modulacion de ire1.
US9266892B2 (en) 2012-12-19 2016-02-23 Incyte Holdings Corporation Fused pyrazoles as FGFR inhibitors
HUE036571T2 (hu) 2013-04-19 2018-07-30 Incyte Holdings Corp Biciklusos heterociklusok mint FGFR inhibitorok
US10851105B2 (en) 2014-10-22 2020-12-01 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
US9580423B2 (en) 2015-02-20 2017-02-28 Incyte Corporation Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr) 2015-02-20 2017-12-26 Incyte Corp Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
EP3259269B9 (en) 2015-02-20 2020-03-04 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CN107722012B (zh) * 2016-08-11 2020-05-29 斯福瑞（南通）制药有限公司 制备4-氯-7H-吡咯并[2,3-d]嘧啶的方法
AR111960A1 (es) 2017-05-26 2019-09-04 Incyte Corp Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
CR20200590A (es) 2018-05-04 2021-04-26 Incyte Corp Formas sólidas de un inhibidor de fgfr y procesos para prepararlas
US11174257B2 (en) 2018-05-04 2021-11-16 Incyte Corporation Salts of an FGFR inhibitor
US11628162B2 (en) 2019-03-08 2023-04-18 Incyte Corporation Methods of treating cancer with an FGFR inhibitor
WO2021007269A1 (en) 2019-07-09 2021-01-14 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
KR20220100879A (ko) 2019-10-14 2022-07-18 인사이트 코포레이션 Fgfr 저해제로서의 이환식 헤테로사이클
WO2021076728A1 (en) 2019-10-16 2021-04-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
CA3162010A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Derivatives of an fgfr inhibitor
WO2021113479A1 (en) 2019-12-04 2021-06-10 Incyte Corporation Tricyclic heterocycles as fgfr inhibitors
WO2021146424A1 (en) 2020-01-15 2021-07-22 Incyte Corporation Bicyclic heterocycles as fgfr inhibitors
AR126102A1 (es) 2021-06-09 2023-09-13 Incyte Corp Heterociclos tricíclicos como inhibidores de fgfr

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69837903T2 (de) * 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
UA80171C2 (en) * 2002-12-19 2007-08-27 Pfizer Prod Inc Pyrrolopyrimidine derivatives

Also Published As

Publication number Publication date
GT200600496A (es) 2007-07-17
AR058293A1 (es) 2008-01-30
WO2007066189A3 (en) 2008-08-14
DOP2006000271A (es) 2007-08-15
UY29991A1 (es) 2007-07-31
NL2000337A1 (nl) 2007-06-12
WO2007066189A2 (en) 2007-06-14
PE20071037A1 (es) 2007-11-19

Similar Documents

Publication Publication Date Title
TW200733965A (en) Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7H-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea
RS20050469A (en) Pyrrolopyrimidine derivatives
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
MXPA06002296A (es) Tienopiridina-fenilacetamidas y sus derivados utiles como nuevos agentes antiangiogenicos.
WO2007138472A3 (en) Triazolopyridazine derivatives
TW200728307A (en) Novel spirochromanone derivatives
MY145694A (en) Spiroheterocyclic compounds and their uses as therapeutic agents
TW200728260A (en) Substituted-(quinazolinyl)phenyl thiophenyl-sulfonylureas, methods for making and intermediates thereof
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
UA91129C2 (ru) Производные циклоалкиламинокислот и фармацевтическая композиция, которая их содержит
MY151003A (en) Stable pharmaceutical composition comprising a pyrimidine-sulfamide
ATE440603T1 (de) 8-hydroxychinolinderivate
GEP20105134B (en) Agents for preventing and treating disorders involving modulation of the ryr receptors
JO2646B1 (en) New differentiated cyclic compounds as beta - lactam inhibitors
MXPA02012034A (es) Derivados de tiofeno utiles como agentes anticancerosos.
TW200612936A (en) Indole derivatives
TW200626158A (en) Naphthaline derivatives
WO2003074529A3 (en) iNDOLYL-UREA DERIVATIVES OF THIENOPYRIDINES USEFUL AS ANTI-ANGIOGENIC AGENTS
MX2021011118A (es) Derivados de azolopiridina macrocíclicos como moduladores de eed y prc2.
MX2009007038A (es) Derivados de mononitrato de isosorbida para el tratamiento de trastornos intestinales.
MX2008012093A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de trastornos psicoticos.
WO2004111008A3 (en) Use of a compound of formula i for making a pharmaceutical composition
WO2007146856A3 (en) Substituted gamma lactams as therapeutic agents
MX2009005242A (es) Derivados de 3-(hetero)arilisoquinolinamida sustituida en posición 5, 6 o 7 y uso terapeutico del mismo.
WO2005007642A3 (en) Novel azaheterocyclic amides useful for treating pain